Pharmaceuticals & Medical Devices

The cross-industry significance of the secondary healthcare market

At the ISPO Munich 2012, Karsten Neumann, leader of the practice group payors and politics, held a speech on the cross-industry significance of the secondary healthcare market. In his speech, he addresses three key questions:
1.What opportunities exist in the growing healthcare market and the trend toward prevention?
2.Do sports and healthcare go together at all?
3.What is the right approach for cross-industry interaction?

For the sports industry the secondary healthcare market offers major opportunities to gain market share and benefit from the overall market growth. For the healthcare industry an increasing level of physical activity reduces the burden of disease as well as healthcare spending.

The challenge lies and addressing the different customer groups without harming the brand image. Multi-brand strategies and collaboration models with healthcare players could be good ways of approaching this market.

Significance_of_secondary_healthcare_market  

Pharma in trouble

The pharmaceutical industry is experiencing an unprecedented strategic crisis. Innovation (accounting for around 20% of drug companies' annual sales) is no longer creating the expected market impact due to a lack of results – such as a molecule with a suitable effectiveness profile compared to existing treatments – or more often, due to approval not being granted by the healthcare authorities, which are always focused on the benefit-risk ratio.

At the same time, a growing number of patents are expiring, reinforcing competition from generic drugs. As an example, the sales at risk exceed USD 50 billion for just five blockbuster drugs with sales of over one billion dollars a year: the patents for Lipitor (Pfizer), Plavix (Sanofi-Aventis), Advair/Seretide (GlaxoSmithKline), Enbrel (Amgen) and Diovan (Novartis) will enter the public domain within three years. Finally, the growing pressure to cut budget deficits is fueling anxiety about these developments.
http://www.rolandberger.com/news/2010-11-30-rbsc-news-Pharma_in_trouble.html  

Fight or flight? - Diversification vs. Rx-focus in big pharmaceutical's quest for sustained growth 2010

This study is based on a global quantitative survey supported by in-depth desk research.
The survey results were validated in over 50 CEO and board level face-to-face interviews with top decision makers of leading pharmaceutical groups.

According to 65% of pharmaceutical executives, the pharmaceutical industry is currently experiencing a strategic crisis.
Changing healthcare environments, budget pressures, challenging market access as well as massive patent expiries ask for a review of the traditional business model focusing exclusively on high margin, patent-protected innovative medicine.

The majority of pharmaceutical executives think of diversification as a potential way out of the strategic crisis

http://www.rolandberger.com/expertise/publications/2010-10-25-rbsc-pub-Fight_or_flight.html  

What's next? Innovating the concept of innovation in the pharmaceutical industry(Sep 2009)

Please see the below link

http://www.rolandberger.com/expertise/publications/2009-09-04-rbsc-pub-Whats_next_Innovating_the_concept_of_innovation.html  

Roland Berger study on the healthcare market (July 2008)

Please see the below link.

http://www.rolandberger.com/expertise/industries/pharmaceuticals/2008-07-09-rbsc-pub-Study_healthcare_market.html  

Trends in European healthcare (September 2007)

Please see the below link.

Roland_Berger_Trends_in_European_healthcare_20070901.pdf (PDF, 733 KB)

Sales excellence in the Pharmacy Industry; Maximize the power and endurance of your sales organization (March 2007)

Please see the below link.

Roland_Berger_Sales_excellence_in_the_pharma_industry_20070321.pdf (PDF, 704 KB)

The European pharmaceutical industry: Delivering sales excellence in turbulent times (May 2006)

Please see the below link.

Roland_Berger_study_Sales_excellence_20060608.pdf (PDF, 344 KB)